Medicine and Dentistry
Glycogen Storage Disease Type II
89%
COVID-19 Vaccination
40%
Diseases
34%
Neuromuscular Disease
32%
Enzyme Replacement Therapy
32%
Severe Acute Respiratory Syndrome Coronavirus 2
30%
Inflammatory Disorder
29%
Magnetic Resonance Imaging
25%
Weakness
23%
Infusion
21%
Diaphragm
21%
Polyradiculoneuropathy
19%
Disease Course
17%
Spirometry
15%
Infection
15%
Adverse Event
15%
Myositis
14%
Patient-Reported Outcome
14%
Symptom
14%
Cohort Analysis
12%
Myopathy
12%
Immunosuppressant
12%
Prospective Study
11%
Alglucosidase Alfa
11%
Diagnosis
10%
Disease Activity
9%
Cardiovascular Disease
9%
Systematic Review
9%
Glycogen Metabolism
9%
Side Effect
9%
Early Diagnosis
9%
Diagnostic Error
9%
Magnetic Resonance Imaging of Chest
9%
Muscle Contracture
9%
Muscle Cramp
9%
Autosomal Dominant Inheritance
9%
Neuromyelitis Optica
9%
Plexopathy
9%
Peroneus Nerve Paralysis
9%
TNF Inhibitor
9%
Cytotoxic T-Cell
9%
T-Cell Response
9%
Batten Disease
9%
Endocrine Disease
9%
Obstetrics
9%
Methotrexate
9%
Inflammatory Bowel Disease
9%
Parkinsonism
9%
Randomized Controlled Trial
9%
Humoral Immunity
9%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Immune-Mediated Inflammatory Diseases
63%
Vaccination Policy
57%
Humoral Immunity
33%
Breakthrough Infection
29%
Seroconversion
23%
CD20
17%
Intravenous Immunoglobulin
16%
Immunosuppressive Drug
14%
Omicron Coronavirus Variant
12%
TNF Inhibitor
12%
Inflammatory Disorder
11%
Multiple Sclerosis
11%
Cytotoxic T-Cell
10%
Immunosuppressant
10%
Antibody Titer
9%
CD38
9%
HLA-DR
9%
Ocrelizumab
9%
T Cell Activation
9%
Genotype Phenotype Correlation
9%
Enzyme Activity
9%
Limb
9%
Methotrexate
9%
Inflammatory Bowel Disease
9%
Diaphragm
9%
Magnetic Resonance Imaging
9%
Myasthenia gravis
7%
Monospecific Antibody
6%
Spike
6%
Vaccine Efficacy
5%
Chronic Inflammatory Demyelinating Polyneuropathy
5%
Dynamics
5%
Pharmacology, Toxicology and Pharmaceutical Science
SARS Coronavirus
38%
Inflammatory Disease
29%
Glycogen Storage Disease Type 2
29%
Vaccination Policy
21%
Polyradiculoneuropathy
19%
Replacement Therapy
19%
Disease Activity
19%
Immunoglobulin
16%
Adverse Event
15%
Immunosuppressive Agent
14%
Myositis
14%
Neuromuscular Disease
12%
Myopathy
11%
Infection
10%
Methotrexate
9%
Randomized Controlled Trial
9%
Cardiovascular Disease
9%
Filamin
9%
Myelooptic Neuropathy
9%
Endocrine Disease
9%
Cardiomyopathy
9%
Prospective Study
9%
Syndrome
9%
Myasthenia gravis
9%
Disease
8%
Placebo
8%
Chronic Inflammatory Demyelinating Polyneuropathy
7%
Deterioration
7%
Motor Neuropathy
7%
Symptom
5%
Cohort Study
5%
